Cervical Cancer

Adding Pembrolizumab to Chemotherapy Extends Survival in Women with Cervical Cancer Across Several Key Subgroups

The addition of pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in significantly and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in women with cervical cancer.

Results 1 - 1 of 1

Home
Issues
Special Issues
- Supplements
  - ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
    - Checkmate 9LA
- Guide to New FDA Approvals
Categories
Conference Correspondent
- ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Quick Quiz
CE
About

To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".

I'd like to receive:

TOP Print Edition

TOP Weekly e‑Newsletter

I have reviewed and consent to the terms of TOP's Privacy Policy, and TOP has my permission to retain my information in its database, and to forward pertinent communications to me.